Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 May;28(5):501-502.
doi: 10.1038/s41422-018-0031-9. Epub 2018 Mar 28.

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

Jonathan Pol  1   2   3   4 , Guido Kroemer  5   6   7   8   9   10
Affiliations
Comment

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

Jonathan Pol et al. Cell Res. 2018 May.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mechanisms of action of CTLA-4-targeting antibodies. a Traditional view suggesting that optimal antibodies must block the interaction between the co-inhibitory receptor CTLA-4 on effector T cells (Teff) and its ligand B7–1 or B7–2 expressed on APCs. b Alternative view suggesting that CTLA-4 antibodies must eliminate Tregs from the tumor bed by bridging CTLA-4 expressed on the Treg surface to Fc receptors on NK cells or macrophages (MΦ) to mediate ADCC. c Uncoupling efficacy and toxicity of ipilimumab in mouse models of cancer. When administered to mice with a fully ‘humanized’ Ctla4h/h genotype, ipilimumab combined with PD-1-specific antibodies induces autoimmune disease, but no such effect is detected in heterozygous Ctla4h/m mice. In contrast, ipilimumab has similar anticancer effects against tumors implanted in Ctla4h/h and Ctla4h/m mice. Moreover, alternative anti-CTLA4 antibodies may mediate reduced pro-autoimmune effects yet have similar anticancer efficacy. Note that the effects shown in c are particularly strong when anti-CTLA4 antibodies are combined with antibodies targeting PD-1
See this image and copyright information in PMC

Comment on

References

    1. Sharma P, Allison JP. Cell. 2015;161:205–214. doi: 10.1016/j.cell.2015.03.030. - DOI - PMC - PubMed
    1. Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Annu. Rev. Immunol. 2016;34:539–573. doi: 10.1146/annurev-immunol-032414-112049. - DOI - PubMed
    1. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Oncologist. 2013;18:733–743. doi: 10.1634/theoncologist.2012-0483. - DOI - PMC - PubMed
    1. Du, X. et al. Cell Res.10.1038/s41422-018-0012-z (2018).
    1. Du, X. et al. Cell Res.10.1038/s41422-018-0011-0 (2018).